Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Market Cap	6.75B -56.2%
Revenue (ttm)	3.37B -10.1%
Net Income	408.45M -16.6%
EPS	0.90 -16.6%
Shares Out	452.75M
PE Ratio	16.56
Forward PE	n/a
Dividend	0.32 (2.20%)
Ex-Dividend Date	Jun 3, 2026

Volume	16,004,900
Open	14.85
Previous Close	14.52
Day's Range	14.73 - 15.17
52-Week Range	12.13 - 35.06
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Cisen Pharmaceutical

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal dru...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 3,114
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603367

Financial Performance

In 2025, Cisen Pharmaceutical's revenue was 3.44 billion, a decrease of -13.48% compared to the previous year's 3.98 billion. Earnings were 421.25 million, a decrease of -17.22%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error